PTGX实时信号 | 通过Getagraph.com最大化利润

购买 107753 min ago

@ $27.66

发出时间: 15 Feb 2024 @ 02:56

回报率: -7.83%

上一信号: Feb 14 - 22:30

上一信号: 出售

回报率: 0.75 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:49):

Stats
今日成交量	52 879.00
平均成交量	653 093
市值	1.49B
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $2.51 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-18.34
ATR14	$0.0490 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Ali Asif	Sell	1 234	Common Stock
2024-04-01	Patel Dinesh V Ph D	Sell	25 000	Common Stock
2024-03-07	Selick Harold E	Buy	6 490	Common Stock
2024-03-07	Selick Harold E	Sell	6 490	Stock Option (right to buy)
2024-03-01	Patel Dinesh V Ph D	Sell	30 000	Common Stock

INSIDER POWER
66.88
Last 96 transactions
Buy: 2 575 390 \| Sell: 452 277

音量相关性

長: -0.11 (neutral)

短: 0.47 (neutral)

Signal:(49.194) Neutral

Protagonist Therapeutics 相关性

10 最正相关
ITAQU	0.969
PLYA	0.949
MCAA	0.937
BRLI	0.932
PANL	0.929
IOAC	0.927
RNXT	0.925
MLTX	0.923
RIVE	0.923
ALTR	0.92

10 最负相关
LMPX	-0.928
AROW	-0.921
JAGX	-0.921
ONEM	-0.915
PSHG	-0.91
RPRX	-0.908
GNTY	-0.908
BWB	-0.907
CSSEP	-0.906
BLUE	-0.901

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Protagonist Therapeutics 相关性 - 货币/商品

0.29
( neutral )

0.42
( neutral )

0.00
( neutral )

0.67
( moderate )

0.57
( weak )

-0.81
( strong negative )

Protagonist Therapeutics 财务报表

Annual	2023
营收:	$60.00M
毛利润:	$56.69M (94.48 %)
EPS:	$-1.390

FY	2023
营收:	$60.00M
毛利润:	$56.69M (94.48 %)
EPS:	$-1.390

FY	2022
营收:	$26.58M
毛利润:	$25.55M (96.12 %)
EPS:	$-2.52

FY	2021
营收:	$27.36M
毛利润:	$0.00 (0.00 %)
EPS:	$-2.71

Financial Reports:

No articles found.

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

实时更新： Protagonist Therapeutics [PTGX]

Upcoming Earnings Alert